Peter Mullen

4.7k total citations · 1 hit paper
84 papers, 3.3k citations indexed

About

Peter Mullen is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Peter Mullen has authored 84 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Molecular Biology, 28 papers in Oncology and 21 papers in Cancer Research. Recurrent topics in Peter Mullen's work include Cancer Genomics and Diagnostics (10 papers), HER2/EGFR in Cancer Research (9 papers) and Estrogen and related hormone effects (8 papers). Peter Mullen is often cited by papers focused on Cancer Genomics and Diagnostics (10 papers), HER2/EGFR in Cancer Research (9 papers) and Estrogen and related hormone effects (8 papers). Peter Mullen collaborates with scholars based in United Kingdom, United States and Canada. Peter Mullen's co-authors include Simon P. Langdon, Linda Z. Penn, Rosemary Yu, David J. Harrison, Joseph Longo, Michael C. Archer, Dana Faratian, William R. Miller, Carol Ward and John F. Smyth and has published in prestigious journals such as Cell, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Peter Mullen

81 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The interplay between cell signalling and the mevalonate pathway in cancer

2016 489 citations Peter Mullen, Rosemary Yu et al. profile →

Peers

Countries citing papers authored by Peter Mullen

Since Specialization

Citations

This map shows the geographic impact of Peter Mullen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Mullen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Mullen more than expected).

Fields of papers citing papers by Peter Mullen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Mullen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Mullen. The network helps show where Peter Mullen may publish in the future.

Co-authorship network of co-authors of Peter Mullen

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Mullen. A scholar is included among the top collaborators of Peter Mullen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Mullen. Peter Mullen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Distinct responses to non-autonomous UPRER mediated by glutamatergic and octopaminergic neurons 2025 ·Communications Biology ·(unknown), Adam Hruby, Jing Wang, (unknown), Tripti Nair, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Sean P. Curran, Peter Mullen, Bérénice A. Benayoun, Gilberto Garcia, Ryo Higuchi‐Sanabria	1
2	A phosphoramidate modification of FUDR, NUC-3373, causes DNA damage and DAMPs release from colorectal cancer cells, potentiating lymphocyte-induced cell death 2025 ·PLoS ONE ·(unknown), (unknown), Ying Zhang, Peter Mullen, (unknown), David J. Harrison	0
3	Defining the mode of action of cisplatin combined with NUC-1031, a phosphoramidate modification of gemcitabine 2024 ·Translational Oncology ·(unknown), (unknown), (unknown), In Hwa Um, (unknown), Clarissa Melo Czekster, Peter Mullen, David J. Harrison, (unknown)	1
4	The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent 2023 ·Cancer Chemotherapy and Pharmacology ·(unknown), (unknown), (unknown), Ying Zhang, (unknown), Peter Mullen, Peijun Tang, (unknown), Clarissa Melo Czekster, David J. Harrison	14
5	SARS-CoV-2 infection rewires host cell metabolism and is potentially susceptible to mTORC1 inhibition 2021 ·Nature Communications ·Peter Mullen, Gustavo Garcia, Arunima Purkayastha, (unknown), E. Schmid, Milica Momcilovic, Chandani Sen, Justin Langerman, Arunachalam Ramaiah, David B. Shackelford, Robert Damoiseaux, Samuel W. French, Kathrin Plath, Brigitte N. Gomperts, Vaithilingaraja Arumugaswami, Heather R. Christofk	91
6	A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer 2020 ·Prostate Cancer and Prostatic Diseases ·Joseph Longo, Robert J. Hamilton, Mehdi Masoomian, (unknown), (unknown), Peter Mullen, Mohamad Elbaz, Karen Hersey, Dianne Chadwick, Sangeet Ghai, David W. Andrews, Eric X. Chen, Theodorus van der Kwast, Neil Fleshner, Linda Z. Penn	42
7	Statin-Induced Cancer Cell Death Can Be Mechanistically Uncoupled from Prenylation of RAS Family Proteins 2017 ·Cancer Research ·Rosemary Yu, Joseph Longo, Jenna E. van Leeuwen, Peter Mullen, Wail Ba-Alawi, Benjamin Haibe‐Kains, Linda Z. Penn	53
8	Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer 2015 ·Clinical Cancer Research ·Grant D. Stewart, Fiach C. O’Mahony, Alexander Laird, Lél Eöry, (unknown), Alan Mackay, Jyoti Nanda, Marie O’Donnell, Peter Mullen, S. Alan McNeill, Antony C. P. Riddick, Daniel M. Berney, Axel Bex, Michael Aitchison, Ian M. Overton, David J. Harrison, Thomas Powles	29
9	Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop 2014 ·Cancer Research ·Aleksandra A. Pandyra, Peter Mullen, Manpreet Kalkat, Rosemary Yu, (unknown), Zhihua Li, Suzanne Trudel, Karl S. Lang, Mark D. Minden, Aaron D. Schimmer, Linda Z. Penn	64
10	Effect of Short- and Long-Term Treatment With Valproate on Carnitine Homeostasis in Humans 2012 ·Therapeutic Drug Monitoring ·(unknown), (unknown), Massimiliano Donzelli, (unknown), Peter Mullen, Stephan Krähenbühl	11
11	Proteomic analysis of pre- and post-sunitinib treated renal cancer tissue to assess tumor heterogeneity and differential protein expression. 2012 ·Journal of Clinical Oncology ·Grant D. Stewart, Fiach C. O’Mahony, Lél Eöry, Jyoti Nanda, Alexander Laird, Marie O’Donnell, Peter Mullen, Antony C. P. Riddick, Alan McNeill, Michael Aitchison, Daniel M. Berney, John Peters, Andrea Rockall, Anju Sahdev, Axel Bex, Dana Faratian, Simon Chowdhury, David J. Harrison, Ian M. Overton, Thomas Powles	2
12	Sprouty 2 Is an Independent Prognostic Factor in Breast Cancer and May Be Useful in Stratifying Patients for Trastuzumab Therapy 2011 ·PLoS ONE ·Dana Faratian, Andrew H. Sims, Peter Mullen, Charlene Kay, (unknown), Simon P. Langdon, David J. Harrison	41
13	Trastuzumab and Pertuzumab Produce Changes in Morphology and Estrogen Receptor Signaling in Ovarian Cancer Xenografts Revealing New Treatment Strategies 2011 ·Clinical Cancer Research ·Dana Faratian, Annelien J.M. Zweemer, Yoko Nagumo, Andrew H. Sims, Morwenna Muir, Michael Dodds, Peter Mullen, (unknown), Charlene Kay, Max Hasmann, David J. Harrison, Simon P. Langdon	44
14	Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt 2011 ·Biochimica et Biophysica Acta (BBA) - Molecular Cell Research ·Peter Mullen, Anja Zahno, Peter W. Lindinger, (unknown), Andrea Felser, Stephan Krähenbühl, Karin Brecht	62
15	Tyrosine Phosphorylation Profiling Reveals the Signaling Network Characteristics of Basal Breast Cancer Cells 2010 ·Cancer Research ·Falko Hochgräfe, Luxi Zhang, Sandra O’Toole, Brigid C. Browne, Mark Pinese, (unknown), Gillian M. Lehrbach, David R. Croucher, Danny Rickwood, Alice Boulghourjian, Robert F. Shearer, Radhika Nair, Alexander Swarbrick, Dana Faratian, Peter Mullen, David J. Harrison, Andrew V. Biankin, Robert L. Sutherland, Mark J. Raftery, Roger J. Daly	141
16	Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab 2009 ·Cancer Research ·Dana Faratian, Alexey Goltsov, (unknown), Anatoly Sorokin, Stuart Moodie, Peter Mullen, Charlene Kay, In Hwa Um, Simon P. Langdon, Igor Goryanin, David J. Harrison	126
17	Pseudomembranous gastritis, hepatitis and iritis complicating carbimazole therapy for Graves disease 2005 ·Gretchen Oswald, Peter Mullen, (unknown)	0
18	Comparison of strategies targeting Raf-1 mRNA in ovarian cancer 2005 ·International Journal of Cancer ·Peter Mullen, Fiona McPhillips, Brett P. Monia, John F. Smyth, Simon P. Langdon	7
19	Clinical importance of intratumoral aromatase 1998 ·Breast Cancer Research and Treatment ·William R. Miller, Peter Mullen, (unknown), J. Michael Dixon	30
20	BRCA1 5382insC mutation in sporadic and familial breast and ovarian carcinoma in Scotland 1997 ·British Journal of Cancer ·Peter Mullen, WR Miller, James Mackay, David Fitzpatrick, SP Langdon, Jon Warner	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact